Angiodroid S.P.A.

Based in Bologna, Italy, Angiodroid S. P. A. develops innovative healthcare solutions focused on enhancing diagnostic and interventional procedures, particularly through their advanced CO₂ Injector for Carbon Dioxide Angiography.

Angiodroid S. P. A. was founded in 2013 in Bologna, Italy, by Sebastiano Zannoli, who has a background in medical device innovation.

The company specializes in Carbon Dioxide Angiography solutions. Angiodroid has completed 3 deals, with the latest funding round being Series A, where they raised EUR 7. 000 mn on February 23, 2023, led by CDP Venture Capital and supported by investors including 8a+ Investimenti SGR S. p.

A and ALIAD. The total amount raised so far is EUR 7. 000 mn, and the company's current valuation stands at EUR 36. 180 mn.

Angiodroid specializes in advanced healthcare solutions that significantly enhance diagnostic and interventional procedures. At the core of their offerings is the CO₂ Injector, a device designed for Carbon Dioxide Angiography, which utilizes natural gas as a safe contrast medium for peripheral diagnostic procedures. This technology aims to preserve renal function and improve patient outcomes by minimizing the risks associated with traditional iodine-based contrast agents. Accompanying the CO₂ Injector are disposable products, including a Single Use Adaptor and a Procedural Kit, catering to healthcare professionals in various settings.

Angiodroid's products are utilized by hospitals and healthcare centers primarily across Europe, focusing on improving patient care and facilitating rapid access to life-saving treatments globally. In 2023, Angiodroid reported a revenue of EUR 3,941,728. 80, with an EBITDA of EUR -624,797. 20.

Revenue is generated through direct sales of the CO₂ Injector and its associated disposable products, marketed primarily to healthcare institutions via a B2B model. Transactions typically involve bulk orders and long-term partnerships with healthcare providers, ensuring continuous access to their innovative medical devices. Following the Series A funding raised in February 2023, Angiodroid S. P.

A. plans to leverage the EUR 7. 000 mn to pursue an international market approach, strengthen partnership alliances, and support product development initiatives. The company is focused on launching new products and expanding into additional markets, with specific targets for growth yet to be publicly detailed.